Enveric Biosciences Secures Fourth Patent for Non-Hallucinogenic Neuroplastogenic Drug Candidates
核心洞察
Enveric Biosciences (搜索) received a Notice of Allowance from the USPTO for its fourth patent covering the EVM401 (搜索) series of neuroplastogenic molecules designed for non-hallucinogenic treatment of neuropsychiatric conditions.
The patent, titled "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives," expands Enveric's intellectual property portfolio and strengthens its pipeline targeting neuropsychiatric and addiction disorders (搜索).
The company's lead candidate EB-003 represents the first known compound designed to selectively engage both 5-HT₂A (搜索) and 5-HT₁B (搜索) receptors for fast-acting antidepressant and anxiolytic effects without hallucinogenic properties.
Enveric Biosciences (搜索) has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its EVM401 (搜索) series of neuroplastogenic molecules, marking the fourth patent to be issued for this drug development program targeting mental health disorders without hallucinogenic effects.
The USPTO issues a Notice of Allowance after determining that a patent should be granted from an application. This latest patent, entitled "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives," will further broaden Enveric's pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules and strengthening its capacity to target neuropsychiatric and addiction disorders (搜索) for patients with limited treatment options.
Expanding Neuroplastogenic Portfolio
"Enveric is pleased with this upcoming addition to its overall patent estate and the growing pipeline of potential EVM401 (搜索) molecules," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "This expansion of Enveric intellectual property demonstrates the Company's ability to develop next-generation, non-hallucinogenic neuroplastogens intended for potential treatment of neuropsychiatric conditions."
The patent allowance represents a significant milestone for Enveric's intellectual property strategy, as the company continues to build a protected library of chemical structures designed to promote neuroplasticity without the hallucinogenic effects typically associated with traditional psychedelic compounds.
Novel Therapeutic Approach
Enveric Biosciences (搜索) is focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. The company leverages a differentiated drug discovery platform and a growing library of protected chemical structures to advance novel compounds designed to promote neuroplasticity without hallucinogenic effects.
The company's lead candidate, EB-003, represents a breakthrough in this field as the first known compound designed to selectively engage both 5-HT₂A (搜索) and 5-HT₁B (搜索) receptors. This dual-receptor approach is intended to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience, potentially addressing significant limitations in current mental health treatment options.
Addressing Treatment Gaps
The EVM401 (搜索) series targets neuropsychiatric and addiction disorders (搜索), areas where patients often have few therapeutic options. By developing non-hallucinogenic neuroplastogens, Enveric aims to provide treatments that can promote beneficial neuroplastic changes while maintaining the safety profile necessary for widespread clinical use.
The patent protection for these molecules strengthens Enveric's position in the emerging neuroplastogen field, providing the company with exclusive rights to develop and commercialize these novel therapeutic approaches for treating mental health conditions.